Firm
Counsel are expecting policies that are favourable to patent owners and say the fear factor over applying for patents may diminish
Tilleke & Gibbins’s Indonesia director explains why the firm’s regional presence is a blessing, the threat posed by new practices, and where she sees opportunities
Jane Møller Nielsen explains why a love for linguistics can help build a successful IP career, and reveals the Pippi Longstocking quote that inspires her
The UK Supreme Court will hear another trademark case in Dairy UK v Oatly, this time centring on the registrability of regulated terminology
Sponsored
Sponsored
-
Sponsored by Saint Island International Patent & Law OfficesChiu-ling Lin of Saint Island International Patent & Law Offices discusses a ruling by the Supreme Administrative Court in Taiwan that highlights the importance of claim definiteness and enabling requirements in crystalline form patent cases -
Sponsored by Tilleke & GibbinsAfter decades of debate, Vietnam has recognised the need to create a court dedicated to intellectual property matters, says Loc Xuan Le of T&G Law Firm LLC (TGVN), the local associate firm of Tilleke & Gibbins
-
Sponsored by Gün and PartnersSelin Sinem Erciyas and Zeynep Çağla Üstün explore whether Turkey, as a non-EU state party to the European Patent Convention, might still face the Unified Patent Court’s jurisdiction under EU regulations
-
Sponsored by Tahota Law FirmCharles Feng, Lian Xue, and Yifan Lu of Tahota Law Firm explore Beijing's pioneering role among eight Chinese provinces and municipalities designated to work on the development of the country’s data intellectual property rights framework
-
Sponsored by Spoor & FisherNew patent and utility model procedures and updated fees form part of a legislative update to the Bangui Agreement that became effective in the new year, explains Craig Kahn of Spoor & Fisher Jersey
-
Sponsored by MaiwaldChristian Meyer and Gisela Grabow of Maiwald explore proposed changes to new EU provisions aimed at facilitating faster market entry for generics and biosimilars, so as to allegedly bolster competition and enhance patient access
